| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Bis(maltolato)oxovanadium(IV) targets protein tyrosine phosphatases (PTPs), including PTP-1B, which are negative regulators of insulin signaling. By inhibiting PTPs, BMOV enhances insulin receptor phosphorylation and downstream signaling, leading to increased glucose uptake and improved glycemic control. The compound also activates insulin receptor kinase and modulates various signaling pathways involved in glucose metabolism. BMOV's insulin-mimetic effects make it a valuable tool for studying insulin signaling and diabetes.
|
|---|---|
| ln Vitro |
Treatment with bis(maltose)vanadyl(IV) increases the phosphorylation of Akt, an important insulin signaling intermediary, and the insulin receptor. In C2C12 cells, treatment with bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) also increases the absorption of glucose [1].
In vitro, bis(maltolato)oxovanadium(IV) enhances insulin signaling and glucose uptake in cells. It inhibits protein tyrosine phosphatases (PTPs), leading to increased insulin receptor phosphorylation and activation of downstream signaling pathways. In cell-based assays, BMOV treatment results in increased glucose uptake, enhanced glycogen synthesis, and improved insulin sensitivity. The compound's effects on insulin signaling are assessed using Western blot and glucose uptake assays. These studies confirm the compound's mechanism of action as an insulin-mimetic agent. |
| ln Vivo |
The metabolic phenotype of C57BL/6J mice was enhanced by treatment with bis(maltose)vanadium (IV) (BMOV; 0.75-3.0 mmol; i.p.; twice weekly; for 6 weeks). All tissues examined, including the liver, skeletal muscle, and adipose tissue, had considerably lower PTP activity than those of HFD mice [1].
In vivo, bis(maltolato)oxovanadium(IV) has been studied for its potential in the treatment of diabetes mellitus. Orally administered BMOV improves glycemic control in animal models of diabetes, reducing blood glucose levels and improving insulin sensitivity. The compound's effects on glucose metabolism and insulin signaling have been demonstrated in preclinical studies. Comprehensive in vivo efficacy studies are needed to fully characterize its therapeutic potential. BMOV is a valuable research tool for studying diabetes. |
| Enzyme Assay |
In vitro enzyme assays for BMOV involve measuring the inhibition of protein tyrosine phosphatase (PTP) activity. The enzyme is incubated with a phosphopeptide substrate and varying concentrations of BMOV. The dephosphorylation of the substrate is measured, and the IC₅₀ is calculated. These assays confirm the compound's mechanism of action as a PTP inhibitor.
|
| Cell Assay |
In vitro cell-based assays for BMOV evaluate its effects on insulin signaling and glucose uptake. Cells, such as adipocytes or hepatocytes, are cultured and treated with BMOV, and insulin receptor phosphorylation is assessed by Western blot. Glucose uptake is measured using radiolabeled 2-deoxyglucose or fluorescent glucose analogs. These assays confirm the compound's functional activity as an insulin-mimetic agent.
|
| Animal Protocol |
Animal/Disease Models: High-fat diet (HFD) fed C57BL/6J mice (4-6 weeks) [1]
Doses: 0.75-3.0 mmol Route of Administration: intraperitoneal (ip) injection; twice a week; for 6 weeks Experimental Results: Improved metabolism Phenotype, manifested by weight loss, improved insulin sensitivity and glucose tolerance. In vivo animal experiments for BMOV have been conducted in animal models of diabetes, such as streptozotocin-induced diabetic rats or genetically diabetic mice. Animals are treated with BMOV orally, and blood glucose levels are monitored over time. Insulin sensitivity and glucose tolerance are assessed. Pharmacokinetic studies are conducted to determine the compound's half-life, clearance, and tissue distribution. Comprehensive in vivo studies are available from preclinical research. |
| ADME/Pharmacokinetics |
BMOV is absorbed after oral administration and is distributed to various tissues. The compound has a molecular weight of 317.15 g/mol. It is soluble in organic solvents. The compound's half-life and excretion profile have been characterized in preclinical studies. BMOV is for research use only.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BMOV has been evaluated in preclinical studies. The compound is generally well-tolerated at therapeutic doses. Common side effects may include gastrointestinal disturbances. Comprehensive toxicological studies are needed to fully characterize the safety profile of BMOV. The compound is for research use only.
|
| References |
|
| Additional Infomation |
Bis(maltolato)oxovanadium(IV) (BMOV) is a coordination complex of vanadium(IV) with two maltol ligands that functions as a potent insulin-mimetic agent. It has a molecular formula of C₁₂H₁₀O₇V and a molecular weight of 317.15 g/mol. BMOV is an orally active vanadium compound that has been studied for its potential in the treatment of diabetes mellitus. It enhances insulin signaling and glucose uptake in cells. BMOV is a valuable research tool for studying insulin signaling and diabetes.
|
| Molecular Formula |
2[C6H5O3-].OV+2
|
|---|---|
| Molecular Weight |
317.1451
|
| Exact Mass |
316.986
|
| CAS # |
38213-69-3
|
| PubChem CID |
3035454
|
| Appearance |
Brown to black solid powder
|
| Boiling Point |
284.7ºC at 760mmHg
|
| Flash Point |
127.3ºC
|
| LogP |
1.463
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
202
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XUOLEICXAPEOSI-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C6H6O3.O.V/c2*1-4-6(8)5(7)2-3-9-4;;/h2*2-3,8H,1H3;;/q;;;+2/p-2
|
| Chemical Name |
2-methyl-4-oxopyran-3-olate;oxovanadium(2+)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~78.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1531 mL | 15.7654 mL | 31.5308 mL | |
| 5 mM | 0.6306 mL | 3.1531 mL | 6.3062 mL | |
| 10 mM | 0.3153 mL | 1.5765 mL | 3.1531 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
